OriGene Technologies Inc announced a research collaboration with Tanox Inc for the functional study of 2,000 full-length human cDNA clones encoding membrane bound proteins. Tanox will reserve the rights for therapeutic applications identified through this collaboration. OriGene will retain the rights for research and diagnostic reagent development.

OriGene Technologies, a research tool provider for functional gene discovery, has utilized high-throughput cloning and expression profiling to isolate and catalog a searchable gene bank of 20,000 full-length human cDNA clones suitable for transfection and direct in vitro expression. Tanox, a biopharmaceutical company, is engaged in the discovery and development of therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

OriGene full-length genes are unidirectionally cloned from reverse-transcribed human cDNA libraries into industry-standard mammalian expression vectors. cDNA inserts are never subjected to PCR amplification, thereby avoiding random mutation and eliminating downstream experimental deviation.